Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2006-09-05
2006-09-05
Andres, Janet L. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C435S069500, C435S007100, C435S335000
Reexamination Certificate
active
07101974
ABSTRACT:
The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders, such as rheumatoid arthritis.
REFERENCES:
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4894439 (1990-01-01), Dorin et al.
patent: 4948875 (1990-08-01), Tanaka et al.
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5028420 (1991-07-01), Masegi et al.
patent: 5081021 (1992-01-01), Mizuno et al.
patent: 5151349 (1992-09-01), Tanaka et al.
patent: 5160483 (1992-11-01), Postlethwaite et al.
patent: 5180811 (1993-01-01), Doerper et al.
patent: 5262309 (1993-11-01), Nakamura et al.
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5597899 (1997-01-01), Banner et al.
patent: 5606023 (1997-02-01), Chen et al.
patent: 5652353 (1997-07-01), Fiers et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5773582 (1998-06-01), Shin et al.
patent: 5888814 (1999-03-01), Kriegler et al.
patent: 5889156 (1999-03-01), Kriegler et al.
patent: 2005051 (1990-06-01), None
patent: 0 251 037 (1988-01-01), None
patent: 0 254 647 (1988-01-01), None
patent: 0 486 908 (1992-05-01), None
patent: 0 251 037 (1994-06-01), None
patent: 60-252496 (1985-12-01), None
patent: 03-180194 (1991-08-01), None
patent: 03-297388 (1991-12-01), None
patent: 04-079880 (1992-03-01), None
patent: 04-182497 (1992-06-01), None
patent: 04-182498 (1992-06-01), None
patent: 04-368398 (1992-12-01), None
patent: 05-255393 (1993-10-01), None
patent: 05-271287 (1993-10-01), None
patent: 05-271289 (1993-10-01), None
patent: WO 90/07579 (1990-07-01), None
patent: WO 94/18325 (1994-08-01), None
patent: WO 98/47089 (1998-10-01), None
patent: WO 98/51344 (1998-11-01), None
patent: WO 00/23564 (2000-04-01), None
patent: WO 01/25277 (2001-04-01), None
Arakawa et al., “Alteration in folding efficiency and conformation of recombinant human tumor necrosis factor-alpha by replacing cysteines 69 and 101 with aspartic acid 69 and arginine 101,”Protein Eng3(8):721-724 (Aug. 1990).
Barbara et al., “Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective,”Immunol Cell Biol74(5):434-443 (Oct. 1996).
Cen et al., “Glycine68 to histidine73 has an important role in the function of human tumor necrosis factor alpha,”Biochem Mol Biol Int43(1):47-52 (Sep. 1997).
Creasey et al., “Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines,”Cancer Res47(1):14-149 (Jan. 1987).
Jones et al., “The three-dimensinal structure of tumour necrosis factor,”Prog Clin Biol Res349:321-327 (1990).
Loetscher et al, “Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors,”J Biol Chem268(35):26350-26357 (Dec.1993).
Masegi et al., “Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity,”Jpn J Cancer Res86(1):72-80 (Jan. 1995).
Narachi et al., “Role of single disulfide in recombinant human tumor necrosis factor-alpha,”J Biol Chem262(27)13107-13110 (Sep. 1987).
Peitsch, M.C. and Tschopp, J., “Comparative molecular modelling of the Fas-ligand and other members of the TNF family,”Mol Immunol. Jul. 1995;32(10):761-72.
Sato et al., “Differentiation induction by a tumor-necrosis-factor mutant 471 in human myelogenous leukemic cells via tumor-necrosis-factor receptor-p55,”Int J Cancer78(2):223-232 (Oct. 1998).
Shin et al., “A novel tumor necrosis factor-alpha mutant with significantly enchanced cytotoxicity and receptor binding affinity,”Biochem Mol Biol Int44(6):1075-1082 (May 1998).
Tavernier et al., “Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis,”J Mol Biol211(2):493-501 (Jan. 1990).
Van Ostade, X., et al., “Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis,”Embo J10(4):827-836 (1991); Erratum inEmbo J11(8):315 (1992).
Van Ostade et al., “Structure-activity studies of human tumour necrosis factors,”Protein Eng7(1):5-22 (Jan. 1994).
Van Ostade et al., “Two conserved tryptophan residues of tumor necrosis factor and lymphotoxin are not involved in the biological activity,”FEBS Lett238(2):347-352 (Oct. 1988).
Van Ostade, “Human TNF mutants with selective activity on the p55 receptor,”Nature361:266-269 (Jan. 1993).
Xi et al., “Biological activities of human tumor necrosis factor-alpha and its novel mutants,”Biochem Mol Biol Int38(4):855-862 (Apr 1996).
Xi et al., “Biological activities of human tumor necrosis factor-alpha and its novel mutants,”Biochem Mol Biol Int38(6):1183-1189 (May 1996).
Yamagishi et al., “Mutational analysis of structure-activity relationships in human tumor necrosis factor-alpha,”Protein Engineering3(8):713-719 (1990).
Yamamoto et al., “Histidine-15: an important role in the cytotoxic activity of human tumor necrosis factor,”Protein Eng2(7):553-558 (May 1989).
Zhang et al., “Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship,”J Biol Chem267(33):24069-24075 (Nov. 1992).
Li, Y. et al., “PEGylated Recombinant Human Tumor Necrosis Factor Alpha: Pharmacokinetics and Anti-tumor Effects,” Biol. Pharm. Bull. 24(6):666-670 (2001).
Menart, V, et al., “Early events in TNFa-p55 receptor interations-experiments with TNF dimers.” Pflugers Arch. 2000;439(3 Suppl):R113-5.
Williams-Abbott, L, et al., “The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand.” J Biol Chem. 1997 Aug. 1;272(31):19451-6.
Ngo et al., Computational Complexity, Protein Structure Prediction and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, 26(37):8509-8517.
Watson, “TNF inhibitors: A review of the recent patent literature”, IDrugs, 2002, 5(12):1151-1161.
Dahiyat Bassil I.
Filikov Anton
Andres Janet L.
Seharaseyon Jegatheesan
Silva Robin M.
Xencor
LandOfFree
TNF-αvariants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-αvariants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-αvariants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585170